Gestational diabetes & diabetes in pregnancy
Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial
Authors' conclusion
Empagliflozin had no significant effect on beta-cell function in women with recent GDM. Given the sample size evaluated in this trial, the use of SGLT-2 inhibitors warrants further study to elucidate their potential impact on T2DM prevention in women with previous GDM.
Study context
- Population
- Women with recent GDM (6–36 months postpartum)randomized 1:1
- Participants
- 91 women
- Comparison
- Empagliflozin 10 mg/day vs placebo for 48 weeks
- Primary endpoint
- Baseline-adjusted ISSI-2
- Follow-up
- 48 weeks
Methodological detailsdouble-blind, placebo-controlled, randomized 1:1
- Double-blind
- Placebo-controlled
- Randomized 1:1
Primary result
As reported in the abstract
Empagliflozin
525
± 30.4
Placebo
560
± 33.4
P = 0.43
Secondary outcomes
Prevalence of dysglycemia (prediabetes/diabetes) · 48 weeks · no difference
P = 0.18
Worsened glucose tolerance
P = 0.08
Additional beta-cell function measures (insulinogenic index/HOMA-IR; ΔCpep0-120/Δgluc0-120 × Matsuda index)
- Did not differ between the groups
Original publication
Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial. Diabetes Obes Metab. Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →